BR0316465A - Composição para o tratamento de infecções por chlamydia e métodos para indentificar as mesmas - Google Patents
Composição para o tratamento de infecções por chlamydia e métodos para indentificar as mesmasInfo
- Publication number
- BR0316465A BR0316465A BR0316465-9A BR0316465A BR0316465A BR 0316465 A BR0316465 A BR 0316465A BR 0316465 A BR0316465 A BR 0316465A BR 0316465 A BR0316465 A BR 0316465A
- Authority
- BR
- Brazil
- Prior art keywords
- cyclophilin
- treatment
- agglutination
- chlamydia
- pairs
- Prior art date
Links
- 208000007190 Chlamydia Infections Diseases 0.000 title abstract 4
- 208000028512 chlamydia infectious disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000001493 Cyclophilins Human genes 0.000 abstract 6
- 108010068682 Cyclophilins Proteins 0.000 abstract 6
- 230000004520 agglutination Effects 0.000 abstract 4
- 241000606161 Chlamydia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"COMPOSIçãO PARA O TRATAMENTO DE INFECçõES POR CHLAMYDIA E MéTODO PARA IDENTIFICAR OS MESMOS". A invenção se refere a modalidades terapêuticas e composições farmacêuticas para o tratamento de infecção por Chlamydia empregando polipeptídeos de ciclofilina e seu par ou pares de aglutinação celular humana correspondente como um alvo para intervenção. A presente invenção se refere ao uso de fontes exógenas ou enxertadas de ciclofilinas, anticorpos anti-ciclofilina, iscas de ciclofilina, formas solúveis de pares de aglutinação a ciclofilina e pequenas moléculas que são fornecidas extracelularmente, e atuam presumivelmente interrompendo-se a aglutinação da ciclofilina A com seu receptor(s) ou par(s) de aglutinação celular, como um tratamento para infecção por Chlamydia. A presente invenção ainda se refere a ensaios de avaliação quanto à identificação de compostos que inibem a interação da ciclofilina e seus pares de aglutinação de Chlamydia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42858502P | 2002-11-22 | 2002-11-22 | |
| PCT/US2003/037617 WO2004047759A2 (en) | 2002-11-22 | 2003-11-24 | Composition for treating chlamydia infections and method for identifying same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316465A true BR0316465A (pt) | 2005-10-11 |
Family
ID=32393426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316465-9A BR0316465A (pt) | 2002-11-22 | 2003-11-24 | Composição para o tratamento de infecções por chlamydia e métodos para indentificar as mesmas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040192591A1 (pt) |
| EP (1) | EP1567864A4 (pt) |
| JP (1) | JP2006507351A (pt) |
| AU (1) | AU2003295903A1 (pt) |
| BR (1) | BR0316465A (pt) |
| CA (1) | CA2506738A1 (pt) |
| MX (1) | MXPA05005465A (pt) |
| WO (1) | WO2004047759A2 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0584343B1 (en) * | 1992-03-10 | 1999-01-20 | La Jolla Cancer Research Foundation | Recombinant calf intestinal alkaline phosphatase |
| ES2065290B1 (es) * | 1993-07-29 | 1995-11-01 | Consejo Superior Investigacion | Utilizacion de inhibidores enzimaticos para el tratamiento de enfermedades causadas por parasitos. |
| US5773225A (en) * | 1994-05-24 | 1998-06-30 | The Trustees Of Columbia University In The City Of New York | Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation |
| DE69841894D1 (de) * | 1997-11-21 | 2010-10-21 | Merck Serono Biodevelopment Sa | Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion |
| US20010048927A1 (en) * | 2000-02-01 | 2001-12-06 | Richard Stephens | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia |
-
2003
- 2003-11-24 BR BR0316465-9A patent/BR0316465A/pt not_active IP Right Cessation
- 2003-11-24 JP JP2004555709A patent/JP2006507351A/ja active Pending
- 2003-11-24 MX MXPA05005465A patent/MXPA05005465A/es not_active Application Discontinuation
- 2003-11-24 US US10/722,695 patent/US20040192591A1/en not_active Abandoned
- 2003-11-24 EP EP03787117A patent/EP1567864A4/en not_active Withdrawn
- 2003-11-24 AU AU2003295903A patent/AU2003295903A1/en not_active Abandoned
- 2003-11-24 WO PCT/US2003/037617 patent/WO2004047759A2/en not_active Ceased
- 2003-11-24 CA CA002506738A patent/CA2506738A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004047759A3 (en) | 2004-12-09 |
| MXPA05005465A (es) | 2005-07-25 |
| EP1567864A4 (en) | 2007-01-03 |
| EP1567864A2 (en) | 2005-08-31 |
| US20040192591A1 (en) | 2004-09-30 |
| AU2003295903A1 (en) | 2004-06-18 |
| JP2006507351A (ja) | 2006-03-02 |
| WO2004047759A2 (en) | 2004-06-10 |
| CA2506738A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erlich et al. | Macrophages, rather than DCs, are responsible for inflammasome activity in the GM-CSF BMDC model | |
| Guha et al. | Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1 | |
| Mouritzen et al. | Immunomodulatory potential of Nisin A with application in wound healing | |
| Sui et al. | CXCL10‐induced cell death in neurons: role of calcium dysregulation | |
| Lindqvist et al. | Autophagy induced during apoptosis degrades mitochondria and inhibits type I interferon secretion | |
| Griffin et al. | Mass spectrometry reveals distinct proteomic profiles in high-and low-quality stallion spermatozoa | |
| Balczon et al. | Role for microtubules in centrosome doubling in Chinese hamster ovary cells | |
| Cleland et al. | Bone protein extraction without demineralization using principles from hydroxyapatite chromatography | |
| Mihailidou et al. | CHOP-dependent regulation of p21/waf1 during ER stress | |
| Sánchez‐Gómez et al. | Amoxicillin haptenates intracellular proteins that can be transported in exosomes to target cells | |
| BR0312913A (pt) | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo | |
| Li et al. | A natural peptide from a traditional Chinese medicine has the potential to treat chronic atrophic gastritis by activating gastric stem cells | |
| Sultan et al. | Evaluation of the antifungal and wound-healing properties of a novel peptide-based bioadhesive hydrogel formulation | |
| Ueda et al. | Prothymosin α plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms | |
| Tseng et al. | Mechanisms underlying the inhibition of murine sperm capacitation by the seminal protein, SPINKL | |
| Petzold et al. | Protein aggregate formation permits millennium-old brain preservation | |
| Zeng et al. | Calmodulin antagonists differentially affect capacitation-associated protein tyrosine phosphorylation of mouse sperm components | |
| Santavanond et al. | The small molecule raptinal can simultaneously induce apoptosis and inhibit PANX1 activity | |
| Reynoso-Ducoing et al. | Analysis of the expression of cytoskeletal proteins of Taenia crassiceps ORF strain cysticerci (Cestoda) | |
| Chakraborty et al. | Anti-inflammatory and anti-fibrotic effects of berberine-loaded liquid crystalline nanoparticles | |
| Finan et al. | Proteomics approach to study the functions of Drosophila myosin VI through identification of multiple cargo-binding proteins | |
| BR0316465A (pt) | Composição para o tratamento de infecções por chlamydia e métodos para indentificar as mesmas | |
| Song et al. | Evaluation of the safety, cell migration, and mucoadhesive properties of a mucoadhesive polymer blend in human oral mucosa | |
| Groen et al. | Microtubule assembly in meiotic extract requires glycogen | |
| US10323078B2 (en) | Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: WYETH (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070101630/RJ DE 24/07/2007. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |